Inovio Pharmaceuticals stock gains as price crosses 200-day moving average
Published on 09/19/2026 at 17:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Inovio Pharmaceuticals stock (ISIN US45773H2013) ended the last completed Nasdaq Capital Market session at USD 1.24 on September 18, 2026, after trading as high as USD 1.27 and moving above its 200-day moving average of USD 1.23 according to MarketBeat.
Stock moves above key moving average
As of the close on September 18, 2026, Inovio Pharmaceuticals stock was quoted at USD 1.24 on the Nasdaq Capital Market, up 2.07 percent from its prior close per a price overview on MarketBeat, implying a modest positive session for investors.
The same overview shows that the shares traded between an intraday low and a high of USD 1.27 on that session, with closing volume reported at 2,889,868 shares on September 18, 2026, according to the alert from MarketBeat.
On a technical basis, the same alert notes that the 50-day simple moving average of Inovio Pharmaceuticals stock stood at USD 1.10 and the 200-day simple moving average at USD 1.23, so the latest close of USD 1.24 placed the stock slightly above both averages on September 18, 2026, marking a small but visible improvement versus the longer-term trend per MarketBeat.
Loss narrows sharply in Q2 2026
Beyond the short-term price move, recent SEC filing analysis highlights a meaningful improvement in Inovio Pharmaceuticals’ bottom line in the second quarter of 2026, with the company reporting no revenue and a net loss of USD 6.0 million, or USD 0.07 per share, compared with a net loss of USD 23.5 million a year earlier, according to StockTitan.
The same analysis attributes much of this year-on-year improvement to a USD 13.9 million non-cash gain from revaluing common stock warrant liabilities, which materially reduced the reported net loss for the quarter even though the company did not generate product revenue in Q2 2026 per StockTitan.
Earlier in the year, Inovio Pharmaceuticals reported a first-quarter 2026 net loss of USD 19.7 million, or USD 0.28 per share, with operating expenses falling to USD 21.9 million from USD 25.1 million as both research and development as well as general and administrative spending decreased versus the prior year according to the same StockTitan summary.
The combination of the narrower USD 6.0 million net loss in Q2 2026 and the larger USD 19.7 million net loss in Q1 2026 indicates that Inovio Pharmaceuticals cut its quarterly net loss by USD 13.7 million between Q1 and Q2, largely thanks to the warrant valuation gain and lower expenses, which is a notable delta for investors tracking the company’s path toward potential profitability, as synthesized from the StockTitan data.
Regulatory catalyst and financing context
From a pipeline perspective, the same SEC-focused overview emphasizes that regulatory progress continued for Inovio Pharmaceuticals’ lead candidate INO-3107 for recurrent respiratory papillomatosis, with the United States Food and Drug Administration reviewing the Biologics License Application under the accelerated approval program and a Prescription Drug User Fee Act (PDUFA) target date set for October 30, 2026, according to StockTitan.
The filing notes that while the FDA has accepted the Biologics License Application for INO-3107, it has also raised questions about eligibility for accelerated approval that will be discussed at a future meeting, highlighting a key regulatory risk factor that could influence the valuation of Inovio Pharmaceuticals stock as the October 30, 2026, target date approaches per the same StockTitan analysis.
In terms of funding its operations, Inovio Pharmaceuticals has turned to the equity markets several times, including an offering of 21,052,632 shares of common stock with accompanying warrants at a combined public offering price of USD 0.95 per share and warrant, which raised USD 20.0 million in gross proceeds per StockTitan.
Furthermore, a separate prospectus supplement filing describes a primary offering of 13,158,000 shares of common stock at USD 1.90 per share, implying gross proceeds of USD 25,000,200 and estimated net proceeds of approximately USD 23 million, with underwriters granted a 30-day option to purchase up to 1,973,700 additional shares, as detailed in a 424B filing summarized by StockTitan.
The same 424B overview notes that shares outstanding stood at 53,571,675 as of September 30, 2025, and would rise to 66,729,675 immediately after the USD 25,000,200 offering, or 68,703,375 if the underwriters’ option were exercised in full, underlining the dilutive impact of the capital raise but also the increased liquidity, according to StockTitan.
Inovio Pharmaceuticals stated that cash on hand together with the net proceeds from this offering would be sufficient to fund operations into the third quarter of 2026, providing investors with visibility on the company’s runway ahead of the October 30, 2026, PDUFA decision for INO-3107, as explained in the same StockTitan filing summary.
Analyst view and valuation context
The technical alert that highlighted Inovio Pharmaceuticals stock crossing above its 200-day moving average also pointed to a supportive analyst backdrop, noting that one equities research analyst has rated the stock Strong Buy, five have issued Buy ratings, one has a Hold rating and one has a Sell rating, for an overall consensus rating of Moderate Buy and a consensus price target of USD 3.17, according to MarketBeat.
The same report recalls that Jefferies Financial Group upgraded shares of Inovio Pharmaceuticals from Hold to Positive and increased its target price from USD 1.80 to USD 3.00 in a research note dated August 13, 2026, suggesting that at the recent close of USD 1.24, the shares were trading well below both the Jefferies target and the USD 3.17 consensus target, offering a quantified gap between the current price and analyst expectations as outlined by MarketBeat.
A broader snapshot on MarketBeat indicates that Inovio Pharmaceuticals stock was trading at USD 1.74 on January 1, 2026, and had declined by 29.0 percent to USD 1.2360 by mid-September 2026, underscoring that the recent move above the 200-day moving average comes against a backdrop of significant year-to-date price weakness.
For investors, this combination of a narrowed net loss in Q2 2026, an approaching PDUFA date for INO-3107 on October 30, 2026, and analyst targets roughly double or more the current share price helps frame both the upside potential and the regulatory and dilution risks embedded in Inovio Pharmaceuticals stock at the closing level of USD 1.24 on September 18, 2026.
Stock level and trading venue
Inovio Pharmaceuticals stock last closed at USD 1.24 on the Nasdaq Capital Market on September 18, 2026, with that price sitting modestly above the 200-day moving average of USD 1.23 and the 50-day moving average of USD 1.10, signaling a slight technical improvement while remaining far below the consensus price target of USD 3.17 cited by analysts in recent coverage.
Key data on Inovio Pharmaceuticals stock
- Company: Inovio Pharmaceuticals, Inc.
- ISIN: US45773H2013
- Ticker: INO
- Trading venue: Nasdaq Capital Market
- Price (as of September 18, 2026, 15:59): 1.24 USD
- Market capitalization: 66,729,675 shares outstanding basis, USD-denominated (as of September 30, 2025 context)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Nasdaq indices
